Hims & Hers Health (HIMS): Q1 2026 Earnings Preview Amid GLP-1 Challenges
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $617 million, up 5% from $586 million in Q1 2025.
- Consensus EPS estimate stands at $0.03, reflecting a sharp decline from $0.20 in the year-ago quarter amid higher costs.
- Company guidance for Q1 revenue is $600-625 million, aligning closely with expectations but below some prior analyst views.
- Subscribers ended 2025 at 2.51 million; focus on retention and average revenue per user (ARPU) around $83 monthly.
- Full-year 2026 guidance: revenue $2.7-2.9 billion, Adjusted EBITDA $300-375 million.
- HIMS stock down ~13% YTD amid GLP-1 regulatory pressures, but up recently ahead of earnings.
Earnings Context and Why It Matters
As HIMS, a leading telehealth platform, prepares to report first quarter 2026 earnings on May 11 after market close, I'm paying close attention to how investors will gauge the company's growth trajectory. The past periods saw explosive demand for GLP-1 (glucagon-like peptide-1) offerings, but now there's clear deceleration. HIMS wrapped up 2025 with revenue of $2.35 billion, a 59% year-over-year increase fueled by weight loss products and subscriber growth to 2.51 million. Regulatory scrutiny on compounded semaglutide and the pivot toward branded drugs from companies like Novo Nordisk introduce notable risks. In my view, these Q1 results will clarify whether core areas—men's health, dermatology, and mental health—can maintain momentum as GLP-1 growth moderates. For everyday investors, strong performance on subscribers or ARPU could underscore the long-term promise of personalized telehealth care, while shortfalls might heighten volatility in this competitive space.
Earnings Expectations
Wall Street's projections for Q1 2026 point to revenue of $616.85-$619.6 million, marking a modest 5-6% rise from $586 million in Q1 2025, according to Yahoo Finance (13 analysts) and Zacks data. This fits squarely within the company's own guidance of $600-625 million from its Q4 2025 earnings call. The EPS consensus sits at $0.03 (11 analysts), a steep drop from $0.20 a year earlier, driven by margin squeezes from elevated marketing, R&D on branded GLP-1s, and supply chain adjustments.
From what I see, the metrics to watch closely include subscriber growth past the 2.51 million at the end of 2025, ARPU holding steady around $83 monthly, and Adjusted EBITDA in the guided range of $35-55 million. HIMS has shown a mixed track record on beats: it topped Q4 2025 EPS ($0.08 versus $0.02 expected) but slightly missed revenue ($618 million versus $619 million); earlier, it handily exceeded Q1 2025 revenue and EPS. Historically, the stock has moved about 10-15% after earnings, particularly on upward guidance revisions.
Market Reaction and Investor Sentiment
Sentiment heading into earnings feels cautiously optimistic to me. HIMS shares have climbed over 30% in the past month, though they're still down 13% year-to-date amid GLP-1 headwinds such as FDA restrictions on compounded versions. Analysts hold a Moderate Buy rating, with price targets averaging $29-32, and they're highlighting the Novo Nordisk partnership for branded Wegovy. On the risk side, we could see guidance misses or subscriber churn; potential upsides lie in core category growth or an improved full-year outlook. Implied volatility points to a roughly 14% stock move following the report.
Forward Outlook and Key Factors to Monitor
After Q1, I'll be tracking whether the company reaffirms its full-year 2026 guidance: revenue of $2.7-2.9 billion (15-24% growth over 2025's $2.35 billion) and Adjusted EBITDA of $300-375 million, implying margins of 11-13%. This outlook hinges on sustained access to compounded semaglutide and smooth progress on the proposed Eucalyptus acquisition, expected mid-2026.
One thing that stands out is subscriber trends, with goals to push beyond 2.51 million, and ARPU growth through tailored offerings in weight loss, menopause care, and labs. Regulatory shifts in GLP-1s are pivotal; moving to branded options may strain short-term margins but could enhance long-term stability. I also checked this using Tickeron’s AI Screener to see how HIMS stacks up against peers on growth metrics.
Keep an eye on cost controls, such as marketing expenses and supply chain improvements, plus expansion in non-GLP-1 areas like men's health and dermatology. Future quarters should show if international push and diagnostics can counter domestic pressures. Strong execution across these could enable steady scaling in telehealth.
Why I Rely on Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener to cut through the noise on stocks like HIMS. This AI-powered tool lets me filter thousands of stocks and ETFs using technical patterns, fundamentals, trends, volatility, and AI signals—customizable by industry, market cap, indicators, price patterns, and more. It surfaces trade ideas, breakouts, and opportunities far faster than manual scans, helping me spot how HIMS compares in the telehealth space. It's become a go-to for efficient, data-driven insights in my analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
HIMS's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HIMS moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HIMS broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.978) is normal, around the industry mean (46.654). P/E Ratio (57.137) is within average values for comparable stocks, (99.739). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.668). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (3.504) is also within normal values, averaging (114.968).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement